Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

White House Reform Chief Was On Boards Of Health Companies With Suspect Practices
Before taking her job as the White House health reform director, Nancy-Ann DeParle earned more than $6 million serving on the boards of major health care corporations, some of which were accused of fraud, mismanagement and regulatory violations during her tenure, the Investigative Reporting Workshop at American University reports on MSNBC.com. Some critics say the corporate relationships could be a conflict of interest for DeParle. Also, while there"s no evidence DeParle was involved in or aware of allegedly fraudulent activities, in three cases, she served on board committees overseeing the companies" legal and regulatory compliance.
generic viagra online
Spanish Study Finds Bullies Have Harassed 14 Percent Of Workers Over Past 6 Months
Although it is a relatively widespread phenomenon, the experts have still not been able to come up with an all-encompassing and precise definition of workplace abuse or bullying. Basing their work on previous literature, David González, of the High Court of Justice of Madrid and José Luís Graña, of the Faculty of Psychology at the Complutense University, have defined it in their study as a "process of systematic and repeated aggression by a person or group towards a workmate, subordinate or superior". Their research has been published in the latest issue of Psicothema.
News of the day
Teach Your Patients About Their Medicines To Avoid Misadventure, UK
The National Prescribing Service Ltd (NPS) is urging health professionals to teach patients how to identify the active ingredient in their medicines to avoid mix ups and adverse events.
Oncology

InfoMedics Presents Studies Highlighting Adults' Experiences With ADHD Drug

InfoMedics, Inc., the patient feedback company, recently co-authored two posters detailing patients" experiences with the attention-deficit/hyperactivity disorder (ADHD) drug lisdexamfetamine dimesylate (LDX). The posters were presented at the American Psychiatric Association (APA) and the College of Psychiatric and Neurologic Pharmacists" (CPNP) annual meetings. Both presented data gathered through the Vyvanse New Start Program, which provides information to prescribing physicians about patients" impressions of LDX treatment and its affect on their ADHD symptoms. "The New Start Program is designed to support effective patient-physician communications," said InfoMedics" Senior Director of Analytic Services Donna Kerney, PhD. "Enhanced communication and brand-specific feedback are enormously helpful to physicians who want to know the impact their prescribed medications have on patients, to the pharmaceutical companies who want to better understand consumers" reactions to their products, and to patients who want their physicians to know how they are doing. Ideally this shared information will lead to improved treatment management and better outcomes for patients." The APA poster presented data for all program participants, while the CPNP poster reported on the survey responses of the subgroup of patients previously treated with mixed amphetamine salts (MAS) extended release. The program surveys were conducted through online and automated telephone surveys at baseline (prior to starting treatment with LDX) and at 3 and 6 weeks later. Overall, both posters showed that between the baseline and six-week surveys, the majority of patients taking LDX experienced improvements in their ADHD symptoms, greater satisfaction than with prior prescription medication, dosage convenience, and good tolerability. Patients also reported significantly less interference of ADHD symptoms with work/school tasks, social/leisure activities, and personal relationships with use of LDX treatment vs. before using LDX. Within both groups, the majority of patients (an average of 80 percent) reported that they intend to continue LDX treatment. The poster presented at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, FL, April 19-22, 2009, was prepared by InfoMedics" Senior Director of Analytic Services Donna Kerney, PhD, in conjunction with Michael Manos, PhD, of Children"s Hospital, Cleveland Clinic, Cleveland, OH; Donna Antonucci, MD, private practice, Yardley, PA; and Anthony DeLeon, PharmD, BCPP, Shire Development Inc., Wayne, PA. The poster presented at the 162nd Annual Meeting of the American Psychiatric Association, was co-authored by Dr. Kerney, Dr. Antonucci and Dr. Manos as well as Frank A. Lopez, MD, Children"s Developmental Center, Winter Park, FL. In both cases, the research was supported by funding from Shire Development Inc. InfoMedics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009